The prime objective of the present multicenter, prospective study was to evaluate the suitability of sentinel lymph node biopsy for patients with node-positive breast cancer before neoadjuvant chemotherapy. The present study enrolled 143 patients with breast cancer with positive axillary nodes at the initial diagnosis. Sentinel lymph node biopsy after neoadjuvant chemotherapy in these patients was technically feasible but should not be recommended for the luminal subtype. Background: Sentinel lymph node biopsy (SNB) is the standard treatment of node-negative breast cancer; however, whether SNB should be performed for patients with node-positive disease before neoadjuvant chemotherapy (NAC) is controversial. We evaluated the accuracy of SNB after NAC in patients with breast cancer with nodal metastasis before chemotherapy to determine the false-negative rate (FNR) and detection rate for SNB. Patients and Methods: In the present multicenter prospective study performed from September 2011 to April 2013, 143 patients with breast cancer and positive axillary nodes, proved by fine needle aspiration cytology at the initial diagnosis (stage T1-T3N1M0), were enrolled. All patients underwent breast surgery with SNB and complete axillary lymph node dissection. Results: After NAC, the pathologic complete nodal response rate was 52.4%. The sentinel lymph node could be identified in 130 cases (90.9%); the FNR was 16.0% (13 of 81). The FNR of each clinical subtype was 42.1% (8 of 19) for the estrogen receptorpositive and human epithelial growth factor 2 (HER2)-negative (luminal type), 16.7% (2 of 12) for ER-positive and HER2positive (luminal-HER2 type), 3.2% (1 of 31) for HER2-positive (HER2-enriched type), and 10.5% (2 of 19) for ER-negative and HER2-negative (triple-negative breast cancer; P ¼ .003). The FNR was significantly greater in the luminal than in the nonluminal type (odds ratio, 9.91; 95% confidence interval, 6.77-14.52). Conclusion: SNB after NAC in patients with initially node-positive breast cancer was technically feasible but should not be recommended for the luminal subtype. However, the tumor subtype can guide patient selection, and axillary lymph node dissection could be omitted for the luminal-HER2, HER2-enriched, and triple-negative breast cancer subtypes.
Introduction
Axillary lymph node status is important both as a prognostic factor in breast cancer [1] [2] [3] and as a factor determining treatment. Previously, axillary lymph node dissection (ALND) was performed to confirm the axillary lymph node status; however, this resulted in postoperative complications such as lymphedema and/or motor deficits in many cases. [4] [5] [6] Therefore, sentinel lymph node biopsy (SNB) was established to evaluate the lymph nodes, and it has recently become a standard treatment for clinically node-negative breast cancer, leading to a comparative decrease in the occurrence of postoperative complications.
Neoadjuvant chemotherapy (NAC) is a common treatment used for patients with locally advanced and lymph node-positive breast cancer to reduce the tumor size, increase the rate of breastconserving surgery, and acquire information regarding chemotherapy sensitivity. The use of SNB after NAC is controversial. A meta-analysis of studies in which SNB was performed after NAC in patients with clinically node-negative cancer showed acceptable accuracy. 7 Nevertheless, ALND remains the standard surgical treatment of node-positive disease; however, negative conversion of lymph node metastasis due to chemotherapy has been reported in approximately 40% of cases. 8, 9 ALND is unnecessary in such cases, and the associated postoperative complications can be avoided if the axillary lymph node status can be accurately evaluated by SNB.
The present clinical trial was designed to determine the accuracy of SNB after NAC in patients who had presented with pathologically confirmed axillary node metastasis before chemotherapy.
Patients and Methods
The present prospective, multicenter study was performed at 8 centers in Japan from September 2011 to April 2013. The inclusion criteria were (1) women aged 20 years; (2) histologically confirmed clinical stage T1 through T3N1M0 primary invasive breast cancer; (3) initially confirmed axillary node metastasis by fine needle aspiration cytology before NAC; (4) completion of NAC (the chemotherapy regimen was determined at the discretion of the treating medical team); (5) tumors negative for lymph node metastasis confirmed by imaging after NAC; and (6) Eastern Cooperative Oncology Group performance status of 0 or 1. The exclusion criteria were a history of bilateral breast cancer, inflammatory breast cancer, ipsilateral breast cancer recurrence, and previous SNB. All patients provided written informed consent. A central ethics committee (Showa University School of Medicine) reviewed the protocol, and the local ethics committees approved it.
Axillary Lymph Node Evaluation
Physical examination and ultrasonography were performed before and after NAC to evaluate whether axillary lymph node metastasis persisted. Node positivity was defined as lymph nodes that were palpable, those > 1 cm in size, those showing reduced fatty deposition, and those demonstrating lateral cortical hypertrophy on ultrasonography.
Surgical Intervention
Surgical resection (breast-conserving surgery or mastectomy) was performed for the primary lesion, and SNB followed by ALND were performed for all the patients. For SNB, a combination of blue dye and radiolabeled colloid agents was recommended to maximize the likelihood of sentinel lymph node (SLN) identification.
Histopathologic Examination
The primary lesion, axillary lymph node status, and various biomarkers were evaluated before and after NAC. For the axillary lymph nodes, data were collected on the number of SLNs, the number of lymph nodes obtained by ALND (non-SLNs), and lymph node status. SLNs were defined as positive for metastasis if residual tumor was observed, regardless of the size. The pathologic stage was determined using the Union for International Cancer Control TNM classification, 7th edition.
The estrogen receptor (ER), progesterone receptor (PgR), and human epithelial growth factor 2 (HER2) status of the tumor was evaluated using immunohistochemical staining of breast specimens obtained using core needle biopsy. For ER and PgR, the tumor was considered positive when the ratio of stained cells was > 10% and the Allred score was 4 to 8, and the tumor was considered negative when < 10% of the cells were stained and the Allred score was 0 to 3. The staining for HER2 was evaluated using the HercepTest (Dako, Glostrup, Denmark). The scoring was interpreted as 0 to 3 according to the American Society of Clinical Oncology/College of American Pathologists guidelines. 10 HER2 was considered positive in cases with immunohistochemistry findings of 3 or with gene amplification observed on fluorescence in situ hybridization.
On the basis of the ER, PgR, and HER2 findings, the clinical tumor subtypes were categorized as follows: luminal type, ERpositive and/or PgR-positive and HER2-negative; luminal-HER2 type, ER-positive and/or PgR-positive and HER2-positive; HER2enriched type, ER-negative, PgR-negative, and HER2-positive; and triple-negative breast cancer (TNBC), ER-negative, PgRnegative, and HER2-negative.
Outcomes
The primary endpoint was the false-negative rate (FNR) of SNB after chemotherapy in patients who were found to have no positive SLN but had 1 positive non-SLNs. The secondary endpoint was the identification rate of the SLNs.
Statistical Analysis
Univariate analysis was performed using the c 2 test and Mann-Whitney U test to evaluate the relationship between the FNR and clinical tumor characteristics. Multivariate analysis was performed using a logistic regression model with statistically significant variables on the univariate analyses. Analyses were performed using the SPSS, version 21.0, statistical software package (SPSS Inc., Chicago, IL), with P < .05 considered significant.
Results

Patient and Tumor Characteristics
A total of 143 patients were enrolled in the study. The patient and tumor characteristics are listed in Table 1 . The median age of the patients at surgery was 51 years (range, 30-74 years). All the cases in the present study were invasive ductal carcinoma. Before NAC, 20 patients (14.0%) had clinical stage IIA, 95 (66.4%) had stage IIB, 20 (14%) had stage IIIA, 7 (4.9%) had stage IIIB, and 1 (0.7%) had stage IIIC tumors. The distribution of the clinical 300 -Clinical Breast Cancer August 2016 SNB After NAC for Initial Diagnosis of Node-positive Breast Cancer tumor subtypes was as follows: 50 (35%) luminal, 25 (17.5%) luminal-HER2, 39 (27.3%) HER2-enriched, and 29 (20.3%) TNBC. After NAC, the primary tumor showed a complete clinical response in 37 (25.9%), a partial response in 96 (67.1%), and no response in 10 (7.0%). The pathologic complete response (pCR) rate of the primary tumors was 37.8%.
Detection of SLNs
Of the 143 patient who underwent SNB lymph node surgery ( Table 2) , 7 (4.9%) underwent the procedure with the blue dye only and 136 (95.1%) with a combination of the blue dye and radiolabeled colloid agents. SLNs were identified in 130 patients (90.9%) and not detected in 13 patients (9.1%). The mean number of removed lymph nodes was 1.6 in 130 patients with identified SLNs. Pathologic examination of the SLNs and non-SLNs removed on ALND revealed no residual nodal disease in 68 of these patients, yielding a complete nodal response rate of 47.6%. A total of 81 cases (62.3%) were negative for SLN metastasis, and 49 cases (37.7%) had 1 positive node. In 13 patients, residual cancer was not identified in the SLNs but was found in the non-SLNs, resulting in an FNR of 16.0% (13 of 81).
The analysis according to the clinical tumor subtype revealed that the rate of SLN identification was 90.0% (45 of 50) in the luminal, 92.0% (23 of 25) in the luminal-HER2, 89.7% (35 of 39) in the HER2-enriched, and 93.1% (27 of 29) in the TNBC subtypes ( Figure 1 ). The clinicopathologic factors affecting the FNR are listed in Table 3 . On univariate analysis, the FNR was significantly lower in the hormone receptor-negative and HER2-positive patients. According to the clinical tumor subtype, the FNR was 42.1% (8 of 19) in the luminal, 16 .7% (2 of 12) in the luminal-HER2, 3.2% (1 of 31) in the HER2-enriched, and 10.5% (2 of 19) in the TNBC subtypes ( Figure 2) , indicating that the FNR was significantly greater in the luminal type than in the nonluminal type (odds ratio, 9.91; 95% confidence interval, 6.77-14.52; Table 4 ).
Discussion
SNB for patients with breast cancer was introduced by Krag et al 11 in 1993, and its use has subsequently increased rapidly. According to large clinical trials and meta-analyses, the FNR was 7.3% to 9.7%. [12] [13] [14] [15] In cases in which the SLN is negative for metastasis, ALND can be omitted without affecting the prognosis, 14, 16 and the rate of postoperative complications is low; therefore, the omission of ALND has become the standard management in such cases.
NAC was introduced for locally advanced breast cancer in the 1970s. The National Surgical Adjuvant Breast and Bowel Project B-18 17 and B-27 18 trials showed no significant differences in the disease-free survival and overall survival between the NAC group and the adjuvant group. Furthermore, in both these studies, patients with a pCR had significantly superior disease-free survival and overall survival compared with patients without a pCR. NAC has become one of the standard treatments of node-positive breast cancer or large tumors. For patients undergoing NAC, it has been recommended that SNB be performed before treatment. 19 According to a retrospective analysis of NAC in a large clinical trial 20 the identification rate was 89.6%, the FNR was 8.4%, and no significant difference in regional recurrence was observed between those who had undergone NAC and those who had not (0.9% vs. 1.2%, respectively; P ¼ .5). From these results, it can be concluded that, with proper care, SNB can be performed in cases without lymph node metastases before NAC and ALND can be omitted.
In cases staged as N1 or higher, the omission of lymph node dissection by SNB is concerning. In 2 clinical trials (American College of Surgeons Oncology Group [ACOSOG] Z1071 trial and Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy [SENTINA]), 21, 22 the validity of SNB after NAC in cases of clinically nodepositive breast cancer was assessed. In the ACOSOG Z1071 trial, 21 756 patients, including 649 with clinical N1 disease, were enrolled. Axillary lymph node metastasis was documented by fine needle aspiration cytology or core needle biopsy. The identification rate of SLNs was 92.9%, and the FNR was 12.6%. However, the FNR differed according to the number of removed lymph nodes; the FNR was 31.5% when 1 SLN was removed, 21% when 2 were removed, and 9.1% when 3 nodes were removed. The SENTINA trial was a large study conducted across 103 institutions in Germany and Austria. 22 Women with breast cancer who were scheduled to receive NAC were enrolled. Women with initially node-positive disease received NAC, and those with conversion to clinically node-negative disease after chemotherapy were treated with SNB followed by ALND. The SENTINA trial revealed an identification rate of 80.1%; the FNR was 24.3% for women with 1 node removed and 18.5% for those with 2 SLNs removed. Thus, both studies showed that the FNR was < 10% only when 3 lymph nodes had been removed.
In recent years, breast cancers have been classified into 4 molecular subtypes according to the combination of hormone receptor and HER2/neu receptor expression. The sensitivity to chemotherapy differs according to the subtype, and subtype diagnosis can influence the appropriate management and drug choice in preoperative treatment. 23 In addition, the subtype is useful for predicting the risk of axillary lymph node metastasis. [24] [25] [26] [27] [28] The use of preoperative treatment with or without the addition of trastuzumab therapy for HER2-positive breast cancer has been reported. A randomized trial by Buzdar et al 29 showed that a significant difference in the pCR rate between patients treated with and without the addition of trastuzumab (65.2% vs. 26.3%, respectively; P ¼ .016). Of the cases enrolled in the present study, 35% were the luminal type, relatively low compared with the generally reported percentages (60%-70%), with a tendency toward the use of NAC, considering the drug sensitivity. In addition, in our study, the SLN identification rate and FNR were shown to vary according to subtype. The ACOSOG Z1071 trial concluded that it is important to remove 2 SLNs for minimizing the FNR and that clip placement could help improve the accuracy of SNB. Our study showed similar data considering the FNR, although > 80% of the patients had had < 2 nodes removed. In particular, those with HER2-enriched and the TNBC subtype had a FNR of 10%.
Although the number of cases examined was limited, the FNR among those with the luminal subtype was high, making it difficult to recommend SNB. In contrast, the FNR among the luminal-HER2, HER2-enriched, and TNBC subtypes was low. Thus, our data suggest that it is possible to guide patient selection according to the clinical tumor subtype.
Conclusion
The results of our prospective study do not recommend the routine use of SNB for evaluating the status of residual axillary metastasis after NAC in patients with initially diagnosed cytologyproven node-positive breast cancer. It is preferable to individualize axillary management after NAC according to the clinical tumor subtype, and it might be possible to perform SNB in selected patients (ie, those with the luminal-HER2, HER2-enriched, or TNBC subtype).
Clinical Practice Points
SNB and ALND is the standard treatment for node-negative and node-positive breast cancer, respectively; SNB and ALND are generally applied during NAC for locally advanced breast cancer. It has been seen that approximately 40% of node-positive cancer will change to node-negative after NAC. Hence, in the present study, we evaluated the accuracy of SNB after NAC in patients with breast cancer presenting with cytology-proven axillary node metastasis before chemotherapy to determine the FNR and detection rate for SNB after chemotherapy in women initially presenting with cytology-proven node-positive breast cancer. The results of the present study have shown that with proper care, SNB can be performed in patients without lymph node metastases before NAC and ALND can be omitted. In addition, the present study showed that it might be possible to perform SNB in selected patients (ie, those with the luminal-HER2, HER2-enriched, and TNBC subtypes). 
